EXHIBIT 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2019
INMUNE BIO INC. |
(Exact name of registrant as specified in charter) |
Nevada |
| 001-38793 |
| 47-5205835 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of incorporation) |
| File Number) |
| Identification No.) |
1224 Prospect Street, Suite 150, La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | INMB | The NASDAQ Stock Market LLC |
Emerging growth company x
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement
On May 20, 2019, INmune Bio Inc. (the “Company”) entered into a sublease with CTI-Clinical Trial Services, Inc. (“Sublease”). The Initial term of the Sublease is sixty-one months commencing upon the substantial completion of certain tenant improvements estimated to by June 1, 2019. During the term of the Sublease the monthly base rent is as follows:
Months |
| Monthly Base Rent |
| |
1-12 months |
| $ | 4,108.75 |
|
13-24 months |
| $ | 4,232.00 |
|
25-36 months |
| $ | 4,358.95 |
|
37-48 months |
| $ | 4,489.72 |
|
49-60 months |
| $ | 4,624.41 |
|
61 month |
| $ | 4,763.14 |
|
Timothy J. Schroder is the Chief Executive officer and owner of CTI-Clinical Trial Services Inc. and is a member of the Company’s Board of Directors.
The foregoing description of the Sublease is qualified in their entirety by reference to the full text of the Sublease, a copy of which is attached hereto as Exhibit 10.1 and which is incorporated herein in its entirety by reference.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| 99.1 | Sublease between INmune Bio Inc. and CTI-Clinical Trial Services, Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| |||
Date: May 24, 2019 | By: | /s/ David Moss | |
| David Moss | ||
| Chief Financial Officer | ||
EXHIBIT 99.1